These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31115879)

  • 1. Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma.
    Ashour R; Ri M; Aly SS; Yoshida T; Tachita T; Kanamori T; Aoki S; Kinoshita S; Narita T; Totani H; Masaki A; Ito A; Kusumoto S; Komatsu H; Mansour S; Elsaied AA; Iida S
    Int J Hematol; 2019 Jul; 110(1):69-76. PubMed ID: 31115879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials.
    Ye W; Wu X; Liu X; Zheng X; Deng J; Gong Y
    BMC Cancer; 2021 Sep; 21(1):994. PubMed ID: 34488679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy.
    Zamagni E; Tacchetti P; Pantani L; Cavo M
    Expert Rev Hematol; 2018 May; 11(5):423-435. PubMed ID: 29582696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma.
    Veillette A; Guo H
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):168-77. PubMed ID: 23731618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns.
    Danhof S; Rasche L; Mottok A; Steinmüller T; Zhou X; Schreder M; Kilian T; Strifler S; Rosenwald A; Hudecek M; Einsele H; Gerhard-Hartmann E
    Ann Hematol; 2021 Jun; 100(6):1537-1546. PubMed ID: 33575947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.
    van de Donk NW; Moreau P; Plesner T; Palumbo A; Gay F; Laubach JP; Malavasi F; Avet-Loiseau H; Mateos MV; Sonneveld P; Lokhorst HM; Richardson PG
    Blood; 2016 Feb; 127(6):681-95. PubMed ID: 26631114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases.
    Ziogas DC; Terpos E; Gavriatopoulou M; Migkou M; Fotiou D; Roussou M; Kanellias N; Tatouli I; Eleutherakis-Papaiakovou E; Panagiotidis I; Ntanasis-Stathopoulos I; Kastritis E; Dimopoulos MA
    Leuk Lymphoma; 2018 Apr; 59(4):983-987. PubMed ID: 28782413
    [No Abstract]   [Full Text] [Related]  

  • 8. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
    Campbell KS; Cohen AD; Pazina T
    Front Immunol; 2018; 9():2551. PubMed ID: 30455698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments.
    Geis M; Nowotny B; Bohn MD; Kouhestani D; Einsele H; Bumm T; Stuhler G
    Commun Biol; 2021 Jan; 4(1):44. PubMed ID: 33420283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal Antibodies for the Treatment of Myeloma: Targeting SLAMF7 and CD38.
    Lonial S
    Cancer J; 2016; 22(1):3-6. PubMed ID: 26841009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double CD38
    Mykytiv V; Alwaheed A; Mohd Hashim NA
    Hematol Oncol Stem Cell Ther; 2019 Mar; 12(1):64-66. PubMed ID: 29079129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.
    Friend R; Bhutani M; Voorhees PM; Usmani SZ
    Drug Des Devel Ther; 2017; 11():893-900. PubMed ID: 28356715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [SLAM family proteins as therapeutic targets in multiple myeloma].
    Tamura H; Ishibashi M; Takahashi H; Inokuchi K
    Rinsho Ketsueki; 2020; 61(7):818-826. PubMed ID: 32759570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Functions of Signaling Lymphocytic Activation Molecule Family Molecules in Multiple Myeloma.
    Ishibashi M; Morita R; Tamura H
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33451089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
    Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
    Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7
    Gogishvili T; Danhof S; Prommersberger S; Rydzek J; Schreder M; Brede C; Einsele H; Hudecek M
    Blood; 2017 Dec; 130(26):2838-2847. PubMed ID: 29089311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin.
    Chen J; Zhong MC; Guo H; Davidson D; Mishel S; Lu Y; Rhee I; Pérez-Quintero LA; Zhang S; Cruz-Munoz ME; Wu N; Vinh DC; Sinha M; Calderon V; Lowell CA; Danska JS; Veillette A
    Nature; 2017 Apr; 544(7651):493-497. PubMed ID: 28424516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/lambda ratios of CD38-gated CD138(+) cells.
    Nakayama S; Yokote T; Hirata Y; Iwaki K; Akioka T; Miyoshi T; Takayama A; Nishiwaki U; Masuda Y; Ikemoto T; Tanaka H; Nishimura Y; Tsuji M; Hanafusa T
    Diagn Pathol; 2012 Sep; 7():131. PubMed ID: 23021410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo.
    Schmidmaier R; Mörsdorf K; Baumann P; Emmerich B; Meinhardt G
    Int J Biol Markers; 2006; 21(4):218-22. PubMed ID: 17177159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.